Sirtuins as endogenous regulators of lung fibrosis: A current perspective.
Lung fibrosis
Mitochondrial metabolism
Myofibroblast
Sirtuin
Therapeutic target
Journal
Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521
Informations de publication
Date de publication:
01 Oct 2020
01 Oct 2020
Historique:
received:
16
06
2020
revised:
26
07
2020
accepted:
01
08
2020
pubmed:
12
8
2020
medline:
2
10
2020
entrez:
12
8
2020
Statut:
ppublish
Résumé
Fibrotic lung diseases qualify among the most dreaded irreversible interstitial pulmonary complications with progressive yet largely unpredictable clinical course. Idiopathic pulmonary fibrosis (IPF) is the most challenging prototype characterized by unknown and complex molecular etiology, severe dearth of non-invasive therapeutic options and average lifespan of 2-5 years in patients post diagnosis. Lung fibrosis (LF) is a leading cause of death in the industrialized world with the propensity to contract, significantly increasing with age. Approximately 45% deaths in US are attributed to fibrotic diseases while around 7% respiratory disease-associated deaths, annually in UK, are actually attributed to IPF. Recent developments in the field of LF have unambiguously pointed towards the pivotal role of Sirtuins (SIRTs) in regulating disease progression, thereby qualifying as potential anti-fibrotic drug targets. These NAD
Identifiants
pubmed: 32781070
pii: S0024-3205(20)30953-X
doi: 10.1016/j.lfs.2020.118201
pii:
doi:
Substances chimiques
Sirtuins
EC 3.5.1.-
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
118201Informations de copyright
Copyright © 2020. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that there is no conflict of interest.